Long-term sustained autoimmune response to beta cell specific zinc transporter (ZnT8, W, R, Q) in young adult patients with preserved beta cell function at diagnosis of diabetes

Autoimmunity

Volumn 46, Issue 1, 2013, Pages 50-61

  Ingemansson, Sofie ^a   Vaziri Sani, Fariba ^a   Lindblad, Ulf ^b   Gudbjornsdottir, Soffia ^c   Törn, Carina ^a  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c NHV   (Sweden)

Author keywords

C peptide; Generalized Linear Regression Model; Glutamic acid decarboxylase autoantibodies; Islet antigen 2 autoantibodies; Islet cell antibodies

Indexed keywords

AUTOANTIBODY; C PEPTIDE; UNCLASSIFIED DRUG; ZINC TRANSPORTER; ZNT8 ARGININE; ZNT8 GLUTAMINE; ZNT8 TRYPTOPHAN;

ADOLESCENT; ADULT; ARTICLE; AUTOIMMUNITY; CELL FUNCTION; CORRELATION ANALYSIS; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE DURATION; FEMALE; FREQUENCY ANALYSIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PANCREAS ISLET BETA CELL; RADIOIMMUNOASSAY; SENSITIVITY ANALYSIS;

ADOLESCENT; ADULT; C-PEPTIDE; CATION TRANSPORT PROTEINS; DIABETES MELLITUS; FEMALE; HUMANS; INSULIN-SECRETING CELLS; LINEAR MODELS; MALE; PROSPECTIVE STUDIES; RADIOIMMUNOASSAY; ROC CURVE; SWEDEN; YOUNG ADULT;

EID: 84872192723     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2012.730585     Document Type: Article

References (29)

1. Wenzlau, J. M., Y. Liu, L. Yu, et al. 2008. A common nonsynonymous single nucleotide polymorphism in the SLC30A8 gene determines ZnT8 autoantibody specificity in type 1 diabetes. Diabetes 57: 2693-2697.
2. Brorsson, C., F. Vaziri-Sani, R. Bergholdt, et al. 2011. Correlations between islet autoantibody specificity and the SLC30A8 genotype with HLA-DQB1 and metabolic control in new onset type 1 diabetes. Autoimmunity 44: 107-114.
3. Wenzlau, J. M., K. Juhl, L. Yu, et al. 2007. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc. Natl. Acad. Sci. USA 104: 17040-17045. (Pubitemid 350210987)
4. Vaziri-Sani, F., S. Oak, J. Radtke, et al. 2010. ZnT8 autoantibody titers in type 1 diabetes patients decline rapidly after clinical onset. Autoimmunity 43: 598-606.
5. Wallensteen, M.,G. Dahlquist, B. Persson, et al. 1988. Factors influencing the magnitude, duration, and rate of fall of B-cell function in type 1 (insulin-Dependent) diabetic children followed for two years from their clinical diagnosis. Diabetologia 31: 664-669.
6. Torn, C., M. Landin-Olsson, A. Lernmark, et al. 2001. Combinations of beta cell specific autoantibodies at diagnosis of diabetes in young adults reflects different courses of beta cell damage. Autoimmunity 33: 115-120. (Pubitemid 32293979)
7. Torn, C., M. Landin-Olsson, A. Lernmark, et al. 2000. Prognostic factors for the course of beta cell function in autoimmune diabetes. J. Clin. Endocrinol. Metab. 85: 4619-4623. (Pubitemid 32157642)
8. Jensen, R. A., L. K. Gilliam, C. Torn, et al. 2007. Multiple factors affect the loss of measurable C-peptide over 6 years in newly diagnosed 15- To 35-year-old diabetic subjects. J. Diabetes Complicat. 21: 205-213. (Pubitemid 47002314)
9. Jensen, R., L. Gilliam, C. Torn, et al. 2007. Islet cell autoantibody levels after the diagnosis of young adult diabetic patients. Diabet. Med. 24: 1221-1228. (Pubitemid 47621798)
10. Littorin, B., G. Sundkvist, B. Schersten, et al. 1996. Patient administrative system as a tool to validate the ascertainment in the diabetes incidence study in Sweden (DISS). Diabetes Res. Clin. Pract. 33: 129-133. (Pubitemid 26281542)
11. Vaziri-Sani, F., A. J. Delli, H. Elding-Larsson, et al. 2011. A novel triple mix radiobinding assay for the three ZnT8 (ZnT8-RWQ) autoantibody variants in children with newly diagnosed diabetes. J. Immunol. Meth. 371: 25-37.
12. Lampasona, V., M. Schlosser, P. W. Mueller, et al. 2011. Diabetes antibody standardization program: First proficiency evaluation of assays for autoantibodies to zinc transporter 8. Clin Chem. 57: 1693-1702.
13. Torn, C., P. W. Mueller, M. Schlosser, E. Bonifacio, and P. J. Bingley. 2008. Diabetes Antibody Standardization Program: Evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia 51: 846-852.
14. Landin-Olsson, M., G. Sundkvist, and A. Lernmark. 1987. Prolonged incubation in the two-colour immunofluorescence test increases the prevalence and titres of islet cell antibodies in Type 1 (insulin-Dependent) diabetes mellitus. Diabetologia 30: 327-332. (Pubitemid 17083702)
15. Verge, C. F., D. Stenger, E. Bonifacio, et al. 1998. Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop. Diabetes 47: 1857-1866. (Pubitemid 28549191)
16. Nielsen, L. B., F. Vaziri-Sani, S. Porksen, et al. 2011. Relationship between ZnT8Ab, the SLC30A8 gene and disease progression in children with newly diagnosed type 1 diabetes. Autoimmunity 44: 616-623.
17. Saxena, R., B. F. Voight, V. Lyssenko, et al. 2007. Genomewide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316: 1331-1336. (Pubitemid 46871653)
18. Zeggini, E., M. N. Weedon, C. M. Lindgren, et al. 2007. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 316: 1336-1341. (Pubitemid 46871654)
19. Scott, L. J., K. L. Mohlke, L. L. Bonnycastle, et al. 2007. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316: 1341-1345. (Pubitemid 46871655)
20. Karjalainen, J., P. Salmela, J. Ilonen, H. M. Surcel, and M. Knip. 1989. A comparison of childhood and adult type I diabetes mellitus. N. Engl. J. Med. 320: 881-886. (Pubitemid 19101591)
21. Snorgaard, O., L. H. Lassen, and C. Binder. 1992. Homogeneity in pattern of decline of beta-cell function in IDDM. Prospective study of 204 consecutive cases followed for 7.4 yr. Diabetes Care 15: 1009-1013.
22. Schiffrin, A., S. Suissa, G.Weitzner, P. Poussier, and D. Lalla. 1992. Factors predicting course of beta-cell function in IDDM. Diabetes Care 15: 997-1001.
23. Vermeulen, I., I. Weets, M. Asanghanwa, et al. 2011. Contribution of antibodies against IA-2beta and zinc transporter 8 to classification of diabetes diagnosed under 40 years of age. Diabetes Care 34: 1760-1765.
24. Andersson, C., K. Larsson, F. Vaziri-Sani, et al. 2011. The three ZNT8 autoantibody variants together improve the diagnostic sensitivity of childhood and adolescent type 1 diabetes. Autoimmunity 44: 394-405.
25. Yang, L., S. Luo, G. Huang, et al. 2010. The diagnostic value of zinc transporter 8 autoantibody (ZnT8A) for type 1 diabetes in Chinese. Diabetes Metab. Res. Rev. 26: 579-584.
26. Kawasaki, E. 2012. ZnT8 and type 1 diabetes [Review]. Endocr. J., doi:10.1507/endocrj.EJ12-0069.
27. Long, A. E., K. M. Gillespie, S. Rokni, P. J. Bingley, and A. J. Williams. 2012. Rising incidence of type 1 diabetes is associated with altered immunophenotype at diagnosis. Diabetes 61: 683-686.
28. Torn, C., M. Landin-Olsson, J. Ostman, et al. 2000. Glutamic acid decarboxylase antibodies (GADA) is the most important factor for prediction of insulin therapy within 3 years in young adult diabetic patients not classified as Type 1 diabetes on clinical grounds. Diabetes Metab. Res. Rev. 16: 442-447. (Pubitemid 32093928)
29. Trabucchi, A., N. I. Faccinetti, L. L. Guerra, et al. 2012. Detection and characterization of ZnT8 autoantibodies could help to screen latent autoimmune diabetes in adult-onset patients with type 2 phenotype. Autoimmunity 45: 137-142.